Michelle Klein
Pediatric Endocrinology · New York, NYNPI 1366657835
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,816 of the $5,915 with a category attached, or 64.5%. 31 manufacturers reported payments, led by Novo Nordisk at 41.4% of the total. Reporting peaked in 2019 at $2,747 and has fallen 76.4% since, to $649 in 2025.
Across 153 payments — averaging $38.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Ascendis Pharma Endocrinology Inc$443
- GSK$373
- Kaleo, Inc.$341
- Emergent Biosolutions Inc.$340
- Pfizer$166
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$2,09935%
- Food & beverage$3,81665%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $2,448 |
| Ascendis Pharma Endocrinology Inc | 16 | $443 |
| GSK | 17 | $373 |
| Kaleo, Inc. | 16 | $341 |
| Emergent Biosolutions Inc. | 1 | $340 |
| Pfizer | 7 | $166 |
| Merck | 7 | $148 |
| Amneal Pharmaceuticals LLC | 6 | $142 |
| Sanofi Pasteur Inc. | 4 | $135 |
| Tolmar Pharmaceuticals, Inc. | 6 | $132 |
| Genentech USA, Inc. | 7 | $124 |
| AbbVie | 4 | $113 |
| Ipsen Biopharmaceuticals, Inc | 5 | $104 |
| Azurity Pharmaceuticals, Inc. | 5 | $101 |
| Amgen | 5 | $101 |
| AstraZeneca(2 entities) | 4 | $88 |
| Hologic Sales And Service, LLC | 3 | $79 |
| Tolmar, Inc. | 2 | $75 |
| Endo Pharmaceuticals Inc. | 3 | $62 |
| Sobi, Inc | 2 | $51 |
| IBSA Pharma Inc. | 2 | $47 |
| Endo USA, Inc. | 2 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| Neurocrine Biosciences, Inc. | 1 | $37 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Sanofi | 1 | $31 |
| Sandoz | 1 | $30 |
| Seqirus USA Inc | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Cranial Technologies, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Norditropin$2,099
- Vaxchora$340
- Vivotif$340
How this compares
$5,915 in reported general payments places this provider in the 75th percentile of 138 pediatric endocrinology providers in New York.
Other pediatric endocrinology in New York
- Robert RapaportNew York$98K
- Christopher RomeroNew York$35K
- Vidhu ThakerNew York$33K
- Natasha LeibelNew York$24K
- Mabel YauNew York$19K
- Ilene FennoyNew York$19K
- Emily BreidbartNew York$18K
- Madeleine HarbisonNew York$12K
- Charles SklarNew York$12K
- Oksana LekarevNew York$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.